[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612750":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":54,"collaborators":19,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":19,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":19,"enrollmentInfo":66,"targetDuration":19,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":38,"whyStopped":19,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T cells","EXPERIMENTAL","IL-5 CAR-T cells",[13],"Drug: IL-5 CAR-T cells",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Each subject receive IL-5 CAR T-cells by intravenous infusion",[9],null,[21],{"name":22,"affiliation":23,"role":24},"He Huang, MD","First Affiliated Hospital of Zhejiang University","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Songmin Ying, MD","CONTACT","0571-88208002","yings@zju.edu.cn",{"name":32,"role":28,"phone":33,"phoneExt":19,"email":34},"Yongxian Hu, MD","057187233772","huyongxian2000@aliyun.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"The first affiliated hospital of medical college of zhejiang university","RECRUITING","Hangzhou","Zhejiang","310003","China","CN",{"type":45,"coordinates":46},"Point",[47,48],120.16142,30.29365,{"lat":48,"lon":47},[51,53],{"name":22,"role":28,"phone":33,"phoneExt":19,"email":52},"hehuangyu@126.com",{"name":32,"role":28,"phone":33,"phoneExt":19,"email":34},{"type":24,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"He Huang","Clinical Professor","100612750","phase-1-il-5-car-t-cell-therapy-for-refractoryrelapsed-eosinophilic-leukemia-100612750",false,"NCT07257640","IL-5 CAR-T Cell Therapy for Refractory\u002FRelapsed Eosinophilic Leukemia","The Safety and Efficay Investigation of IL-5 CAR-T Cell Therapy for Patients With Refractory\u002FRelapsed Eosinophilic Leukemia","Inclusion Criteria:\n\n* 1.Male or female patients aged ≥18 years;\n* 2.Diagnosis of eosinophilic leukemia (EL) established according to the WHO 2022 diagnostic criteria;\n* 3.Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts.\n* 4.Meet any of the following criteria for refractory\u002Frelapsed eosinophilic leukemia:\n* a) Inadequate response to standard therapy: failure to achieve complete remission (CR) after standard treatments (e.g., imatinib, corticosteroids, interferon-α, chemotherapy, etc.);\n* b) Disease progression\u002Frelapse within 6 months after achieving remission;\n* 5.Serum total bilirubin ≤1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN;\n* 6.Left ventricular ejection fraction (LVEF) \\>50% as assessed by echocardiography;\n* 7.Peripheral oxygen saturation (SpO₂) ≥92% on room air (without supplemental oxygen);\n* 8.Estimated life expectancy \\>3 months;\n* 9.Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* 10.Women and men of childbearing potential must agree to use appropriate, effective contraception prior to study entry, throughout the study period, and for 6 months after cell infusion (the safety of this therapy for unborn children is unknown and may pose potential risks);\n* 11.Patients who are willing to participate in this study and who are able to understand and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* 1.History of epilepsy or other central nervous system (CNS) disorders;\n* 2.Presence of any of the following:Hepatitis B surface antigen (HBsAg)-positive; Any of HBeAg, HBeAb, or HBcAb positive and detectable hepatitis B virus (HBV) DNA in peripheral blood above the lower limit of detection; Hepatitis C virus (HCV) antibody-positive; Human immunodeficiency virus (HIV) antibody-positive; Positive serologic test for syphilis;\n* 3.History of QT interval prolongation or severe cardiac disease;\n* 4.Presence of uncontrolled active infection;\n* 5.Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the interpretation of the study results.","ALL","18 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.",[74,75],"Hematologic Diseases","Neoplasms",[77,78],"IL-5 CAR-T","Eosinophil","2025-12-03",{"date":81,"type":82},"2025-12-10","ACTUAL",{"date":84,"type":68},"2025-11-30",{"date":86,"type":68},"2028-11-30",{"name":5,"class":6},1]